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ABSTRACT
The AIDS epidemic in the Developing World represents a major global crisis. It is imperative that we develop
an effective vaccine. Vaccines are economically the most efficient means of controlling viral infections. How-
ever, the development of a vaccine against HIV-1 has been a formidable task, and in developing countries
chronic parasitic infection adds another level of complexity to AIDS vaccine development. Helminthic and
protozoan infections, common in developing countries, can result in a constant state of immune activation that
is characterized by a dominant Th2 type of cytokine profile, high IgE levels, and eosinophilia. Such an im-
mune profile may have an adverse impact on the efficacy of vaccines, in particular, an HIV-1 vaccine. Indeed,
the CD8 cellular immune response and the corresponding Th1 type cytokines that enhance the CD8 cellular
immune response are important for clearing many viral infections. It is believed that an antigen specific CD8
cellular immune response will be an important component of an HIV-1 vaccine.
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INTRODUCTION
AT THE CLOSE OF THE 20th century, it became increasinglyapparent to the scientific and medical communities that
Human Immunodeficiency Virus type 1 (HIV-1) was quickly
ravaging populations within the developing world. Since its dis-
covery in 1983, the spread of HIV-1 has been growing at an
alarming rate. As of the end of 2002, an estimated 42 million
people worldwide—38.6 million adults and 3.2 million children
younger than 15 years—were living with HIV/AIDS. Approx-
imately 70% these people (29.4 million) live in Sub-Saharan
Africa; another 17% (7.2 million) live in Asia (UNAIDS. AIDS
Epidemic Update, December, 2002). Despite years of research,
and the development of pharmaceutical agents in the fight
against this disease, there remains no completely effective med-
ical cure or vaccine. While investigating clinical and immuno-
logical methods of treatment for HIV-1, researchers have be-
gun to explore other health issues endemic to the developing
world, and the impact of these diseases on the morbidity and
mortality of the HIV-1–positive native communities.
Parasitic infection and HIV-1 infection coexist in many de-
veloping countries, and this is gaining increasing attention. The
World Health Organization (WHO) reports that preventable in-
fectious disease is the leading killer of impoverished popula-
tions in developing countries throughout the world. They specif-
ically argue for health models that explore the impact of abject
poverty and unsanitary living conditions on the health of mi-
nority populations throughout the developing world. The WHO
states that over 40 million people are severely disfigured and
disabled by filariasis, 200 million people are infected by schis-
tosomiasis, and an additional 12 million people are infected
with leishmaniasis (World Health Organization, 2000). Chronic
parasitic infection is of particular importance due to increasing
rates of HIV-1 infection in regions where parasitic infection is
also endemic throughout the world. Thus, the need for a thor-
ough examination of parasitic infection and HIV-1 vaccine de-
velopment is necessary to advance in the fight against
HIV/AIDS in both the developed and developing nations. We
will explore the complications that arise for developing a vac-




The mechanism of inducing an immune response through
vaccination or antigen presentation is illustrated in Figure 1.
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Taking an example from history, the most successful vaccine
was the smallpox vaccine. This vaccine was a live attenuated
vaccine that induced both antibody as well as cellular immune
responses. However, because of the nature of HIV-1, insertion
and a high rate of mutation, it is likely that no level of attenu-
ation will ever overcome potential safety issues. Yet, in de-
signing a vaccine, a look to what has been observed in persons
infected with HIV-1, perhaps individuals who are long-term
nonprogressors, may provide clues as to what types of immune
responses may limit HIV-1 replication.
The humoral response
Antibodies are important in preventing susceptible cells from
becoming infected by blocking pathogen binding and entry into
CD4 cells or macrophages. The humoral arm of the immune
system has provided protective responses in several successful
viral vaccines. For example, the quantitation of serum neutral-
izing activity in recipients of polio or influenza vaccines has
shown to correlate with the efficacy of the vaccine in prevent-
ing disease following later exposure to the pathogen. In addi-
tion, vaccines against viral diseases such as rabies and hepati-
tis B have produced high-titer neutralizing antibodies, which
have been correlated with vaccine efficacy (Hilleman, 1999).
Neutralizing and crossreactive neutralizing antibodies
against HIV-1 have been observed in populations of long-term
survivors (Cao et al., 1995). Further, higher serological immu-
nity has been observed in mothers who do not transmit infec-
tion to their babies (Rossi et al., 1989; Ugen et al., 1992, 1997).
It appears neutralizing antibodies are susceptible to the anti-
genic diversity of the HIV-1 envelope. Therefore, while type-
specific neutralizing responses can certainly be protective, there
are extremes in the breadth of their protection.
The cellular immune response
Cytolysis induced by cytotoxic T-lymphocytes (CTLs) has
also been shown to correlate with protection in several vaccine
models including influenza. Cytotoxic T lymphocytes kill virus-
infected cells by recognizing viral fragments expressed on the
surface of infected cells associated with the host-specific ma-
jor histocompatability complex (MHC) class I. Cells that are
infected with virus are most likely to be cleared by a specific
CTL response. Indeed, a number of anecdotal reports of pre-
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FIG. 1. Antigen presentation to lymphocytes induces an antigen specific immune response. Antigens are presented to the im-
mune system either during infection or by vaccination. CD4 cells are activated through the T-cell receptor binding to peptides
presented by MHC class II molecules. CD8 activation occurs through MHC class I presentation. B lymphocytes directly interact
through extracellular antigens coming in contact with the B cell receptor.
sumed successful protection from HIV-1 infection have shown
specific CTL activity. Shearer and colleagues have identified a
subset (7 out of 20) of occupationally exposed but uninfected
health care workers with evidence of a transient HIV-1 specific
CTL response (Pinto et al., 1995). CTLs targeted at particular
HIV-1 epitopes were also found in a number of chronically ex-
posed prostitutes who continue to resist infection with HIV-1
(Rowland-Jones et al., 1995). In addition, HIV-1 Gag-specific
CTL has been demonstrated in an uninfected perinatally ex-
posed child (Rowland-Jones et al., 1993). Finally, patients
mounting strong gp160-specific cytotoxic T-lymphocyte re-
sponses have shown a rapid reduction of acute viremia and anti-
genemia, and a high level of CTL activity has been associated
with long-term survival (Borrow et al., 1994; Hulskotte et al.,
1995).
There also appears to be a correlation between long-term
nonprogression and the ability of lymphocytes from these sub-
jects to proliferate to HIV-1 antigens. In particular, it has been
demonstrated that long-term nonprogressors maintain a healthy
proliferative response to HIV-1 core protein p24 (Rosenberg et
al., 1997; Migueles et al., 2002). This is in contrast to most
other HIV infected individuals, in whom the T-cell response to
HIV is weak or completely undetectable even at early stages of
infection when CD4 numbers are still within normal ranges.
Finally, b-chemokines were identified by Gallo and col-
leagues as important contributors to the anti-HIV suppressor
activity of CD81 cells (Cocchi et al., 1995). Levy and col-
leagues (Mackewicz et al., 1991) performed the initial charac-
terization on HIV-1 suppressor molecules released by CD81
cells and described two repeatedly exposed but uninfected in-
dividuals whose CD41 cells resisted infection by primary HIV-
1 isolates and produced elevated levels of the HIV-1 inhibitory
b-chemokines (J.A. Levy et al., 1996).
HIV-1 VACCINE DESIGN: MULTIPLE
ANTIGENS, MULTIPLE TARGETS
Human immunodeficiency virus is an RNA retrovirus be-
longing to the lentivirus family. The HIV-1 genome is orga-
nized into three major structural and enzymatic genes, two reg-
ulatory genes, and four accessory genes. Each of these gene
products represents possible elements for vaccine exploitation
as is detailed below and illustrated in Figure 2.
The envelope
The viral envelope glycoprotein was the first major vaccine
target. The viral envelope binds to CD4 as its first step of in-
fection. In 1996, researchers discovered that a second receptor
was necessary for the entry of HIV-1 into cells. This molecule
was found to be CXCR4, which enables certain strains of HIV-
1 to fuse with and enter T cells. An analysis of the structure of
CXCR4 revealed that it was a receptor for chemokines, the fam-
ily of signaling molecules that includes beta-chemokines.
Shortly following the discovery of the interaction with env and
CXCR4 a second chemokine receptor, called CCR5, was dis-
covered that was necessary for the entry of HIV-1 into macro-
phages. The HIV-1 envelope protein has been included in many
vaccine designs. Predominantly, env is considered to be the ma-
jor target for neutralizing antibody responses. Also, a vaccine
modeled after the very successful Hepatitis B vaccine was the
first HIV-1 vaccine to be tested in animals and humans. How-
ever, it did prove to be effective.
The envelope protein of HIV-1 is the most heterogeneous
of all viral proteins. Also, it may be necessary to include sev-
eral envelopes into a single vaccine. In fact, one of the obsta-
cles to developing a vaccine against HIV-1 is the high muta-
tion rate of the virus. In fact, it is common for several different
variants of the virus to live within one individual. The high
mutation rate is caused by the fact that the reverse transcrip-
tase lacks a proofing function. The mutation rate is estimated
to be one error per round of replication. Over time, the virus
has mutated to create thousands of strains that exist around the
globe. These strains can be categorized into several different
clades or subtypes, designated A through G. A global vaccine
for HIV-1 will need to be crossreactive. Yet, the possibility of
continued mutations to the viral sequence could lead to im-
mune escape.
It is possible that including as many of the viral genes as
possible in a vaccine could combat the sequence variation that
is observed. In a manner that is similar to highly active anti-
retroviral treatment (HAART); if a vaccine can combat the virus
by attacking multiple components, immune escape can possi-
bly be overcome. However, this can only be accomplished by
inducing a cellular immune response since the envelope is the
only protein available to antibody binding.
The viral core
Within the envelope of a mature HIV-1 particle is the cap-
sid, made of 2000 copies of p24. The capsid surrounds two sin-
gle strands of HIV RNA, each of which has a copy of the virus’s
nine genes. The core of HIV-1 also includes p7, the HIV-1 nu-
cleocapsid protein; and p17, or the HIV matrix protein, which
lies between the viral core and the viral envelope. These core
HIV-1 proteins have been included in vaccines predominantly
to induce a cellular immune response against the virus.
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FIG. 2. HIV-1 viral genome. Each component of the HIV-1 genome is a potential target for the immune system.
Following the entry of the virion into the cell the synthesis
of the DNA provirus, a double-stranded DNA version of the
HIV-1 genome, is completed by the viral DNA polymerase and
reverse transcriptase (RT). The DNA provirus is then translo-
cated into the nucleus as a component of the protein–
DNA–preintegration complex, where the viral integrase enzyme
(INT) aids in its incorporation into the host cell genome. After
integration, the DNA provirus replicates with the host cell DNA
every time the cell divides. These genes are now being included
in current vaccine design.
The regulatory genes
The regulatory genes tat and rev affect HIV-1 gene expres-
sion. However, tat transactivation has been shown to increase
viral replication in host cells several 100-fold, and may need to
be eliminated from or certainly attenuated within a potential
vaccine. The rev protein, through its interaction with the Rev-
response element (RRE), increases the number of unspliced
RNAs from the nucleus by its displacement of host splicing fac-
tors which would prevent RNA transport from the nucleus to
the cytoplasm. Rev also plays a major role in the production of
structural proteins of HIV-1; therefore immune responses di-
rected against the rev gene itself could serve to effectively in-
terfere with the viral life cycle (Cullen and Greene, 1990). Ad-
ditionally, the fact that rev is produced early suggests that
immune responses targeting here could be especially important
as well as to those targeted against nef.
The accessory genes
The accessory genes (vif, vpr, vpu, and nef) serve as poten-
tial targets for vaccination as well. These four gene products
are termed “accessory” because of the fact that upon their dele-
tion from the HIV-1 genome, in vitro viral replication remains
intact. The vif (viral infectivity factor) protein, which is located
in the plasma membrane, is important for the production of in-
fectious virions in certain cells (Rosen, 1991). Experiments us-
ing vif mutants elucidated the necessity of vif expression for vi-
ral infectivity of peripheral blood mononuclear cells and
macrophages (Fan and Peden, 1992). Vpu (viral protein u) plays
a role in the downregulation of CD41 cells and the increase of
viral transcription (Klimkait et al., 1990). The vpr (viral pro-
tein r) protein plays several roles including increasing viral
replication, arresting host cell division, and reactivating virus
from a latent phase (D.N. Levy et al., 1993, 1994a, 1994b).
While nef (negative factor) has not been shown to play a crit-
ical role in viral infection of cell lines in vitro (Kim et al., 1989),
experiments conducted with the related simian immunodefi-
ciency virus have shown a decrease in viral replication in rhe-
sus macaques infected with virus with a deletion in the nef gene
(Kestler et al., 1991). More importantly, throughout the follow-
up examination, there was evidence of decreased pathogenesis
of SIV infection observed. This observation was in sharp con-
trast to animals infected with either wild-type nef or virus con-
taining a stop codon within the nef gene. These later animals
produced significantly higher levels of virus, where 5 out of 12
subsequently developed immunodeficiency and died. Finally,
nef appears to provide an important target for cytotoxic T-lym-
phocyte activity.
HIV-1 VACCINES IN DEVELOPMENT
At the beginning of the AIDS epidemic, the vaccine against
hepatitis B proved to be very successful. Given that at that time
there was no cure or even good treatment options for infected in-
dividuals along with the recent success of the protein based hep-
atitis B vaccine, it seemed that a protein vaccine would be the
safest and best choice for an HIV vaccine. Several groups have
reported on the use of recombinant gp120 and gp160, the enve-
lope protein of HIV. All studies have shown that the protein is
well tolerated and safe, but the immune responses generated by
these vaccines are generally not thought to be of a protective level
(Sitz et al., 1999; McCormack et al., 2000; Cunningham et al.,
2001). Protein vaccines drive the immune response towards the
Th2 cellular response and generation of antibodies. However, it
has proven very difficult to raise antibodies against gp120 because
of the high levels of glycosylation and the CD4/gp120 binding
site and the coreceptor binding sites which are deeply recessed
and hidden by the V3 loop, respectively (Kwong et al., 1998).
The 1999 study by Sitz et al. tested recombinant gp160 and re-
combinant gp120 in both low-risk uninfected patients and well as
infected individuals. Although the vaccine posed no threat to safety,
it elicited only weak responses to a small number of peptides, and
no patients responded to the whole gp120 protein (McCormack et
al., 2000). Another study by Nitayaphan et al. (2000) showed that
immunization with 50 mg of rgp120 at months 0, 1, and 4 or 0, 1,
and 6 elicited no more adverse reactions than placebo, and 39 of
52 subjects developed neutralizing antibodies to the homologous
HIVSF2 strain. Twenty-two subjects also developed neutralizing
antibodies against the heterologous strain HIVMN, a laboratory
adapted strain of the virus. However, recent studies have shown
that although HIV infected patients develop neutralizing antibod-
ies against autologous virus, the rate of their production lags be-
hind the mutation rate of the virus (Wei et al., 2003). This group
showed that neutralizing antibodies can neutralize virus isolated
from previous timepoints, but they cannot neutralize virus that is
isolated at the same time as the neutralizing antibodies.
Protein vaccines have been tested in both the United States
and Thailand, and have progressed to Phase III clinical trials.
However, there is increasing concern about their efficacy, as
the trials did not conclusively prove to lower the rate of infec-
tion in HIV negative vaccine recipients (Francis et al., 2003).
Unfortunately, current hope for these vaccines is not high.
The generally low cellular immune responses generated by
protein and peptide-based vaccines have driven investigators to
find adjuvants to enhance the immune response. Several groups
have reported on the use of aluminum hydroxide (alum) as an
adjuvant for both recombinant protein and peptide vaccines.
None of these studies showed serious adverse events with alum,
including a study where infants born to HIV-infected mothers
were given doses up to 300 mg rgp120 with alum adjuvant (Mc-
Cormack et al., 2000; Cunningham et al., 2001; Lambert et al.,
2001). However, alum did not prove to dramatically increase
the immune response. However, not all vaccines and adjuvants
tested have been so innocuous. Toledo et al. (2001) tested
TAB9, a multiepitope vaccine comprising elements of the V3
loop from six HIV-1 isolates that was emulsified in Montanide
120. Twenty-four healthy, low-risk HIV-1 seronegative adult
males received three immunizations of 0, 0.2, or 1 mg at 0, 1,
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and 6 months. At the lowest dose group, seven out of eight re-
cipients experienced severe or local inflammation, and four out
of eight recipients in the higher dose group experienced gran-
ulomas and sterile abscesses. Although there were some safety
issues, the vaccine was immunogenic. All participants in the
vaccine groups produced antibodies that were broadly reactive
against peptides from the MN and IIIB strains, and 50% of sub-
jects were able to neutralize at least one of the five laboratory
isolates tested. The group also observed lymphoproliferation,
with the response being stronger in the higher dose group.
Canarypox
Recombinant canarypox are some of the first and most ex-
haustively tested live recombinant vectors tested in human clin-
ical trials. Canarypox vectors include most of the HIV-1
genes/epitopes and have lead to cellular immune responses in
volunteers. Indeed, these HIV-1 specific CD8 cells were able
to kill peripheral blood mononuclear cells infected with primary
isolates of HIV-1 (Ferrari et al., 1997), and were able to kill
cells infected with HIV from other clades.
DNA vaccines
Another approach to vaccination that has gone to the clinic
is to immunize with plasmid DNA-encoding HIV antigens. As
discussed previously, DNA vaccines are a particularly appeal-
ing strategy for HIV because of their safety, low cost of prepa-
ration and storage, and ease of administration. After establish-
ing safety and immunogenicity in primate models, a DNA
vaccine engineered in our lab was evaluated in a Phase I clin-
ical trial of asymptomatic HIV-infected patients who were not
on antiretroviral therapy (MacGregor et al., 1998). The study
included three groups of patients who were administered three
doses of 30, 100, or 300 mg of plasmid DNA encoding the
env/rev genes. These immunizations were given intramuscu-
larly. The vaccine was well tolerated in all groups, and anti-
body titers against gp120 were increased in the 100 and 300-
mg groups. Individual patients also demonstrated increases in
CTL activity and lymphoproliferation. Following these positive
results, the vaccine was then tested in HIV-negative volunteers
(Boyer et al., 2000). These subjects received four doses of vac-
cine at either the 100 or 300-mg dose level. In the higher dose
group, six out of six patients demonstrated antigen-specific 
lymphoproliferation and production of interferon-g and b-
chemokines. These responses varied by individual and also at
different timepoints in the study.
After the initial success of the first clinical trials of DNA vac-
cines, several labs have developed unique strategies to capital-
ize on the fact that plasmid DNA generally drives a Th1-biased
immune response, generally considered crucial for an effective
vaccine. Several labs, including our collaborators, have sought
to codon-optimize DNA vaccines to enhance the cellular im-
mune response. As described by Qiu et al. (1999), several point
mutations have been made to enhance the secretion of the gag
protein that is translated after transfection in the host. Harriet
Robinson’s group has developed a plasmid that encodes for SIV
gag, pol, vif, vpr, and vpx, as well as HIV env, tat, and rev from
a single transcript in the hopes of boosting the immune response
by giving many different antigenic targets (Amara et al., 2002).
Currently, there are several groups that are trying to maxi-
mize the level of immune responses by first priming with DNA,
then boosting with a live vector. Several live vector expression
systems have been tested in the context of HIV and SIV. These
vectors have been engineered to include various parts of the
HIV genome. This system is attractive because the live vector
allows for the antigen to be presented via the MHC-1 pathway.
Vectors can also be modified so they are replication defective
in the host, thus increasing the safety of this type of vaccine.
Prime-boost strategies
There have been several studies that have tested recombi-
nant canary pox vectors in combination with DNA or recom-
binant protein. The first large-scale prime-boost study using this
vector was done by Belshe et al. (1998), who reported on the
use of ALVAC vCP205 (Pasteur-Meriaux) as the priming vac-
cine. This vaccine is a canary pox vector expression gp120,
p55, and protease. Four hundred thirty-five volunteers, both
low- and high-risk individuals, received four doses at 0, 1, 3,
and 6 months. A control group received no boost, and the ex-
perimental group received a boost of recombinant gp120. Neu-
tralizing antibodies to the MN strain were stimulated in 94%
of the volunteers given vCP205 and gp120 and in 56% of vol-
unteers given vCP205 alone. CTL responses in this study were
intermittent, with 33% of the volunteers in either group re-
sponding at some time point during this study. This study was
very promising, as the results of the prime-boost regimen
proved to be superior to either vaccine given alone.
Bures et al. (2000) reported on a study where patients were
given one of three different canary pox expression vector cod-
ing for the membrane anchored region of HIV-1 MNgp120 fol-
lowed by a boost with a soluble gp160 hybrid consisting of
MNgp120 and the majority of gp41 from HIV-1IIIB. This study
mainly focused on the elicitation of neutralizing antibodies.
They found that the majority of neutralizing antibodies were
specific for the MN-V3 loop, and that despite MN-specific 
neutralization titers exceeding 1:500 at some timepoints, no
neutralization of primary isolates was detected. Little to no 
neutralization of HIV-1IIIB heterologous lab adapted strains was
detected.
In early 2002, the NIAID decided not to proceed with Phase
III trials of the combination of ALVAC, a canarypox vector
containing env antigens, and AIDSVAX, a gp120 protein based
vaccine (HVTN 2002). This decision was based on results of
earlier trials that showed that the production of interferon
gamma, which is considered to be a partial correlate of protec-
tion, was very low as detected by ELISpot. ELISpot is a very
sensitive assay that can detect a frequency as low as one in 1 3
106 cells producing IFN-g after antigen-specific stimulation.
There are several prime-boost combinations that are still in
macaque trials that have shown good results thus far, and pro-
vide hope that these results can be duplicated in humans. Merck
has done a study in which rhesus macaques were given either
plasmid DNA encoding the SIV gag gene alone, DNA with a
modified vaccinia Ankara (MVA) boost, and DNA with a re-
combinant adenovirus (Ad5) boost (Shiver et al., 2002). Some
animals also received an adjuvant known as CRL1005, a non-
ionic blocked copolymer adjuvant, or alum—however, the mag-
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nitude of this effect was not as great as the effect of the prime-
boost regimen. They observed that the animals that received the
Ad5 generated the highest immune responses as measured by
levels of circulating antigen-specific CD81 T-cells and control
of infection after SHIV challenge. However, while the initial
results of the trial were very promising, the group has recently
reported that several of the macaques in the trial have experi-
enced breakthroughs in viral load more than 1 year after the
challenge (10th Conference on Retroviruses and Opportunistic
Infection, Boston, MA, 2003).
As alluded to previously, Harriet Robinson’s group has com-
pleted a trial in macaques to evaluate the DNA plasmid en-
coding the SIV genes gag, pol, vif, vpr, and vpx as well as HIV
env, tat, and rev in a single expression vector along with an
MVA boost (Amara et al., 2002). The MVA was recombinant
for SIV gag and pol and HIV env under the control of vaccinia
virus promoters. Animals were given DNA at weeks 0 and 8,
boosted with MVA at week 24, and challenged with SHIV 89.6
7 months after the boost. Interestingly, the group showed that
while route of administration did not have a significant effect
of the cellular response, animals receiving DNA intradermally
had a 10-fold higher level of antibody production. Two weeks
after the challenge, animals that received the prime and boost
demonstrated at least a one log difference in viral load, and
have since been able to control viral replication to very low lev-
els.
As of yet, there are no vaccines that appear to be able to in-
duce an effective response against HIV-1. However, it has be-
come clear that a Th1 CD4 response and the corresponding CD8
response will be important to suppressing HIV-1 infection. It
is believed that IL-4 and IFN-g are directly in competition and
IL-4 has a negative impact on the CD8 immune response.
PARASITIC INFECTION AND HIV-1 
VACCINE DEVELOPMENT
Helminth infections are characterized by highly polarized
Th2 cytokine responses. They have been shown to modulate
the immune responses to nonparasite or heterologous antigens
by suppression of Th1 cytokines production and enhancing Th2
cytokine secretion in experimental animal models. In fact, sup-
pression of IFN-g to tetanus toxoid following tetanus vaccina-
tion has been shown to occur in humans infected with On-
chocera volvulus and Schistosoma mansoni (Sabin, et al., 1996;
Rowe et al., 2000). Such a phenomenon could bias the effec-
tiveness of any vaccine not only by affecting the induction of
IFN-g but also by altering the function of CD8 cells (Fig. 3).
Berzofsky and colleagues were the first to test this hypoth-
esis in the mouse model. Utilizing S. manosi, they infected
Balb/c mice and demonstrated that a biased Th1 response could
lead to a down regulation of functional CTL following vaccinia
vaccination (Actor et al., 1993). More recently, Bot demon-
strated the impact of IL-4 on CD8 responses. Using a trans-
genic mouse which expresses IL-4 under a lung specific pro-
moter, Bot found that infiltration of CD8 cells into the lungs
was decreased when the transgenic mice were challenged with
influenza (Bot et al., 2000). The ability of the mice to clear het-
erologous infection was delayed. Importantly, the CD8 re-
sponse, however, was not completely abrogated. Indeed, we
have observed in an L. major infection model the number of
vaccine-induced antigen-specific CD8 cells that are able to se-
crete IFN-g is reduced in the parasitically infected mice (Boyer
et al., unpublished results). The most simplistic view is that IL-
4 inhibits the production of Th1 type cytokines, and therefore,
the development of a CD8 cellular immune response.
PARASITIC INFECTION
Fontanet et al. (2000) conducted an epidemiological study
of parasitic disease and HIV infection among sugar-estate res-
idents in Ethiopia. Not surprisingly, this study revealed that
70.1% of the inhabitants had at least one parasitic infection and,
between 3–5% of the workers were HIV seropositive. They con-
cluded that HIV seropositive patients had an increased risk of
amoebic infection as a result of chronic immunosuppression. A
similar study conducted by Wiwanitkit explored the presence
of intestinal parasites among HIV positive patients in Thailand
(Wiwanitkit, 2001). This study concluded that opportunistic
parasitic infections showed the highest prevalence among pa-
tients with CD4 counts below 200/ml. Each of these studies re-
flects the need for increased research in the field of parasitic
and HIV coinfection, and moreover, the need to examine these
diseases in relationship to the community and the available pub-
lic health resources.
The biology
Parasites within the genera Trypanosoma, Leishmania, and
Schistosomiasis are prevalent throughout Africa and some parts
of Asia, and consequently, have severely hindered medical in-
terventions for both HIV-positive and -negative populations.
Trypanosoma is caused by hemoflagellates belonging to the
complex Trypanosoma genus and two morphologically undis-
tinguishable subspecies of Trypanosoma brucei, which cause
distinct disease patterns in humans (CDC, 2001). Within the
medical community, Trypanosoma is widely recognized as the
cause of various forms of African Sleeping Sickness, a disease
that a results in fever and flu-like symptoms, and eventual in-
volvement of the central nervous system. This parasite is trans-
mitted by the tsetse flies of the genus Glossina, as they take a
blood meal on infected mammals (CDC, 2001). These parasites
undergo several stages of growth, and development within the
salivary glands and gut of the host fly, and then are transmit-
ted to another host mammal through an insect bite. Metacyclic
trypanosomes are inoculated, and subsequently, they multiply
in the host’s blood and extracellular fluids including spinal
fluid. Like other parasites, infection with Trypanosoma results
in chronic immune activation, and thus hinders the body’s abil-
ity to counteract any further infection, including HIV.
Leishmania is another parasite that is attracting increasing
attention from the medical community due to its prevalence in
developing countries. There are many forms of Leishmania, in-
cluding cutaneous and visceral. The WHO has reported that
there is alarm at the sharp increase in cases of visceral leish-
maniasis, a deadly form of the disease (as opposed to the less
pathogenic cutaneous form) due to coinfections with HIV
(WHO, 2000). This parasite is transmitted by the bite of female
phlebotomine sandflies (CDC, 2001). Like Trypanosomes,
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these flies become infected following a blood meal on an in-
fected host, and within the sandflies, the parasites differentiate
into promastigotes that mature and multiply. The fly regurgi-
tates these promastigotes during the subsequent blood meal on
the next host, and the promastigotes that reach the puncture
wound are phagocytized by macrophages, where they reside
(CDC, 2001). Leishmania infection is characterized by internal
organ damage, skin lesions, and mutilation of the nose and
mouth. Certain strains of this parasite are not able to be cleared
by the immune system and reside in the macrophages for the
lifetime of the infected individual.
Schistosomiasis is caused by digenetic blood trematodes, and
thus, is primarily transmitted through multiple uses of unsani-
tary waterways. Dessein et al. (2001) state that following pen-
etration of the skin by the free-swimming larvae, Schistosomes
live in the blood of the human host either in the mesenteric
veins or in the vesical plexus. Chronic infection is caused by
eggs that are trapped in tissue of the urinary tract or in the liver.
In patients that are unable to overcome the initial scarring that
results from inflammation, fibrotic tissue may accumulate
around the eggs and in the portal spaces, which can cause ob-
struction of the blood flow in the portal system. These patients
may die of hypertension, varices, coinfection, or heart failure.
These studies show that Trypanosoma, Leishmania and chronic
Schistosomiasis infection have severe biological ramifications
that are only complicated further by HIV/AIDS coinfection.
The immune response
An examination of the impact of parasitic infection on the
developing world is of increasing importance due to the im-
munological impact of these chronic diseases on the body’s
immune system, and thus, the body’s ability to counter addi-
tional infectious diseases, specifically HIV. An investigation of
the immunological record of helminth parasites reveals that in-
fection is accumulative and chronic, and immunity is rare in
most cases (Allen and Maizels, 1996). Thus, many patients suc-
cumb to rapid reinfection following drug treatment. It has been
shown, however, that immunity does aid in limiting the extent
of infection, with adults becoming less likely to be reinfected
than children. This is particularly true among patients suffering
from infection with Schistosomiasis. Many studies investigat-
ing parasitic infection, immunity, and vaccines have centered
on the role of T-cell subsets and cytokine production.
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FIG. 3. Parasites induce a Th2 polarized immune response. The immune activation observed during parasite infection includes
increased production of IL-4. IL-4 can directly inhibit the production of IFN-g and reduce the desired Th1 and CD8 cellular im-
mune response to various vaccines including HIV-1.
Th1/Th2 polarization is most striking in parasitic infection,
and reflects a complex results in the induction of Th2 cell sub-
sets within the murine model. Researchers have demonstrated
that helminthic infection results in the induction of Th2 cell
subsets within the murine model. This is illustrated by the up-
regulation of interleukin IL-4 and the subsequent down regula-
tion of IFN-g. Sher et al. have explored the role of macrophages
in response to cutaneous leishmaniasis in nonvaccinated, in-
fected BALB/c mice (Scott, 1983). They determined that the
selective induction of the Th2 cytokines in this inbred strain re-
sults in suppression of macrophage-mediated clearance of the
parasite. Sher et al. cite a Mosmann and Moore study (1991),
which demonstrated that the Th1/Th2 imbalance induced in
schistosomiasis can be interpreted as the manifestation of cy-
tokine crossregulation. Th1 cytokines are defective due to their
inability to differentiate. This results from the upregulation of
IL-4 synthesis. In addition, IL-10 acts to inhibit IFN-g by block-
ing the production of the TNF-alpha triggering signal, result-
ing in the inhibition of the NO effector pathway for parasite
killing. The studies of Pearce et al. (1991), Gazzinelli et al.
(Sher et al., 1992), and Heinzel et al. (1991) support Sher’s ar-
gument that parasitic infection is characterized by the down-
regulation of cell mediated immunity, and the upregulation of
inhibitory cytokines IL-10 and IL-4. Parasitic infection within
the murine model has presented a clear illustration of the cross-
regulation of cytokines, and the delineation between Th1 and
Th2 cell subsets in response to infection.
Having examined the murine model, it is necessary to ex-
amine the current human clinical research. Studies conducted
by Butterworth (Capron et al., 1984) and Hagan (de Andres et
al., 1997) and reviewed by Allen and Maizels reveal that the
most effective immune combination to combat chronic para-
sitic infection is IgE and eosinophils. Although these cells are
noneffector T cells and derive from Th2-mediated mechanisms,
they have been shown to contribute to the reduction of para-
sitic load. Allen and Maizels state that mast cells in the mucosa
generate physiological changes in the gut that lead to worm ex-
pulsion through the release of a large battery of biologically ac-
tive mediators. Moreover, they state that surface-bound IgE,
and the increased plasma levels of IgE following infection pos-
sible serve to focus mast-cell mediator release against parasites.
Thus, although it is evident that the immune system has devel-
oped methods to control parasitic infection, the inability of the
body to develop a primary Th1 immune response to infection
has resulted in chronic and fatal infection, illustrated by cell an-
ergy and immune suppression.
Within clinical human studies, it has become evident that in
association with specific parasites, including lymphatic filaria-
sis, the body’s T cells are unable to differentiate and prolifer-
ate, thus inhibiting any protective immune response. The stud-
ies of King et al. (1993), and Allen and Maizels (1996) suggest
that this hyporesponsiveness seems to represent selective an-
ergy of the Th1-type cells, in that Th2-type cytokine produc-
tion is relatively undiminished. Borkow et al. (2000) researched
signal transduction and anergy in association with helminth in-
fections in Eastern African populations. Their subject group
also included HIV-positive patients, and thus, they examined
this diverse group’s ability to handle parasitic load. Their re-
search reveals that chronic immune activation that results from
parasitic infection severely compromises one’s ability to pro-
tect oneself from HIV. Hyporesponsiveness and anergy were
indicated by defective or lacking of early transmembrane sig-
naling (phosphorylation and/or dephosphorylation of tyrosine
kinases), lack of attenuated phosphorylation of downstream ki-
nases, such as ERK and p38, and reduced proliferative capac-
ity after antigen stimulation. These impairments of signal trans-
duction pathways result in a biased Th2 response, and an
inability to confer an adequate Th1 protective immune response
against further infection, specifically HIV.
In addition to clinical trials, these theories have been ex-
plored within the murine model. Actor et al. (1993) examined
the ability of Schistosome-infected BALB/c mice to clear vac-
cinia virus. Previous research revealed markedly low CD81
CTL responses, and thus, Actor et al. (1993) hypothesized that
this immune status would compromise the subject’s ability to
clear virus. Accordingly, their research revealed that delayed
clearance is due to the concomitant downregulation in viral-
specific Th1 cytokine and CD81 CTL responses in the doubly
infected animal. Thus, within both clinical and murine models,
it has been demonstrated that a biased Th2 immune response
and downregulation of CD81 cells impair the subject’s ability
to clear additional virus. This is of particular relevance in the
fight against HIV in the developing world, and the search for
adequate and appropriate HIV and parasite vaccines.
CONCLUSION
In discussing parasitic disease, vaccine development and
HIV infection, it becomes apparent that there is a strong cor-
relation between poverty, unsanitary living conditions, parasitic
infection, compromised, and biased immune systems, due to
chronic activation, and fatal HIV infection. Many studies have
demonstrated that the Th2 immunological response that results
from chronic parasitic disease severely hinders the body’s abil-
ity to clear additional virus, specifically HIV. Thus, develop-
ment of vaccine models for both HIV and parasitic infection
must consider and incorporate the immunology of other infec-
tions to adequately and appropriately address the health con-
cerns of the developing world. Bloom argues that “the reality
is millions of people are sick because they are poor, and poorer
because they are sick” (Bloom, 1989). This statement reflects
the complex web of social and economic interaction that must
be examined to provide improved public health measures for
the developing world. Vaccine development, parasitic disease,
and HIV infection must be examined in correlation to the other
health factors that impact specific populations.
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